Khaled Abousaleh
-
12. 09. 24

Zynnon welcomes Dr. Mark Miller as an Advisor

Press Release

Schindellegi, Switzerland, September 12th, 2024

We are pleased to announce that Dr. Mark Miller is joining Zynnon as an Advisor, where he will bring his expertise and leadership to strengthen our Medical Committee on the Advisory Board. 

A world-renowned physician and clinician, researcher and microbiologist, Dr. Miller holds degrees in internal medicine, infectious diseases and clinical microbiology. 

Dr. Miller served for over 11 years (2012-2024) as the Executive Vice President and Chief Medical Officer at bioMérieux SA, a leading global developer and manufacturer of In Vitro Diagnostics (IVD) for infectious diseases.

He was in charge of all medical activities including clinical studies, medical education, and product lifecycle management, as well as numerous market access initiatives related to novel IVD platforms, solutions and reagents for infectious disease diagnostics, all of which addressed important or unmet medical needs.

He retired from bioMérieux in January 2024. Before joining bioMérieux, he spent over 27 years as an academic clinician, researcher, and Full Professor at McGill University in Montreal, Canada, with medical subspecialty training and certification in Internal Medicine, Infectious Diseases, and Clinical Microbiology.

Khaled Abousaleh, CEO of Zynnon comments: “We are truly honored to have Dr. Miller join our team. His extensive research experience and deep expertise in infectious diseases, microbiology and diagnostics are invaluable. We are excited to collaborate with him and anticipate a highly successful and rewarding partnership.”

Dr. Mark Miller states: “It is exciting to see the innovative science and potential applications of Zynnon’s research in the field of infectious diseases diagnostics. Together, we aim to apply these novel discoveries to improve microbiology laboratory efficiency and to benefit patients.”

Zynnon (www.zynnon.com) is a startup transforming infectious pathogen diagnostics, minimizing operations within the laboratory and speeding up the transmission of vital pathogen information to the treating physician in order to optimize treatments and improve patient outcomes. This gaseous biomarker-based solution for the detection of Volatile Organic Compounds (“VOCs”) is used to rapidly and precisely identify bacterial and fungal pathogens to the genus and species level. The VOC-detection and differentiation technology serves as a rapid and efficient alternative or add-on to traditional pathogen identification laboratory methods, substantially shortening the timeline from sample collection to actionable lab results. By streamlining complex procedures into a simple, small, compact, and easy-to-operate sensor-based VOC detector, along with a validated VOC database, the need for specialized laboratory skills for pathogen detection and classification (such as PCR  and/or immunoassay-based techniques) is eliminated.

For media inquiries and additional information, please contact:

Alex Marc

CFO & Investor Relations Manager 

Zynnon AG

Phone: +41 79 455 40 30

Email: alex.marc@zynnon.com